Vous êtes ici

Tryp Therapeutics Inc.

Liste d'échange: 
CSE
Statut: 
Active
Industrie: 
Life Sciences
Symbole: 
TRYP
Indice CSE: 
Devise: 

The Company is a pharmaceutical company focused on bringing transformative medicine with known safety profiles to diseases with no effective first-line treatments. The Company intends to do this through the development of compounds with known activity and/or safety profiles. The Company’s lead program is designed to address neurological disorders through the therapeutic dosing of synthetic psilocybin. The Company is currently evaluating potential lead indications for its psilocybin-for-neurology program, which it refers to as its PFN™ program, including fibromyalgia and Prader-Willi Syndrome. In addition to its PFN™ program, the Company is developing razoxane for the treatment of soft-tissue sarcomas. The Company continues to evaluate potential additional indications for its existing programs, as well as other drug candidates with known activity and/or safety profiles that may have utility in the treatment of rare diseases or other diseases with high unmet medical needs.

Vous êtes ici

Tryp Therapeutics Inc. (TRYP)

SEDAR Information

Information d'entreprise

Addresse
335-1632 Dickson Avenue
Kelowna, BC V1Y7T2
Canada
Téléphone
250-717-1840
Fax
250-717-1845
URL
http://www.tryptherapeutics.com
Date d’inscription à la cote
Mercredi, décembre 16, 2020
Agent de transfert
Capital Transfer Agency

Advertisement

Publicité

Capitalisation

Capitalisation: 
66,320,171
Réservé à l'émission: 
20,433,743

Bulletins

16/12/2020

2020-1225 - Nouvelles inscriptions - Tryp Therapeutics Inc (TRYP)

Le 16 decembre/December 2020

The common shares of Tryp Therapeutics Inc. have been approved for listing on the CSE.

Listing and disclosure documents will be available at www.thecse.com on the trading date.

Advertisement

Publicité

Latest CSE News

Évènements à venir